The African AIDS Vaccine Programme (AAVP)
Request for Small Grants Application
Purpose of grant application
AAVP has obtained funding from a number of Sponsors including the International AIDS Vaccine Initiative (IAVI), the Swedish International Development Cooperation Agency (Sida) and the Canadian International Development Agency (CIDA) to support a small grants funding mechanism to accelerate research in AIDS vaccine in Africa.
This grant will provide a two year funding of $15,000 to $25,000.
The main objective of this program is to support the conduct of research activities in Africa that will contribute to the design of vaccine candidates and to the development of vaccine clinical trails.
South to South collaborations within Africa enhancing the objectives of this grant, promoting mentorship, and highlighting the success of the proposed study are encouraged.
- Community preparedness for AIDS vaccine trials
- HIV incidence studies
- Establishment of normal physiological ranges in African populations (e.g. CD4, hematological normal range and chemistry ranges)
- Social behavioral studies in possible cohorts for vaccine studies
- Development of laboratory techniques to evaluate experimental HIV vaccines
- Supporting national structures for human rights and ethics
- Supporting national regulatory structures
- Establishment or upgrading national database for HIV vaccine use
- Documentation of normal physiological ranges, immunological and/or genetic makeup of African populations Social behavioral studies in possible cohorts for vaccine studies Development of laboratory techniques relevant to the vaccine development of testing Supporting national structures for human rights and ethics Supporting national regulatory structures Establishment or upgrading national and regional databases
Specific focus areas include:
Studies proposed must be realistic in scope. Preliminary data are not a prerequisite for this grant but is encouraged. Participants who have benefited from AAVP workshops are especially encouraged to apply and will be preferentially considered for funding.